Piper Sandler raised the price target for the Replimune Group Inc (NASDAQ:REPL) stock to “an Overweight”. The rating was released on April 17, 2023, according to finviz. The research report from BTIG Research has resumed the stock to Buy, with a price target set at $60. The stock was initiated by BTIG Research, who disclosed in a research note on November 17, 2020, to Buy and set the price objective to $60. In their research brief published November 02, 2020, Jefferies analysts initiated the Replimune Group Inc stock to Buy with a price target of $67.
Historical Earnings Surprises and Revenue Forecasts
Profit is the most critical financial performance measure. Every investor in a business is looking forward to the earnings report as stock price to increase when earnings exceed market expectations and progressively decrease when earnings do not meet expectations. The firm reported an earnings per share (EPS) of -$0.77 during the last quarter as opposed to a consensus estimate of -$0.93, which indicates the company beat its estimate by $0.16, which implies that the company surprised the market by 17.20%. It appears that the average earnings per share estimate for the current quarter (ending in Mar 2024) is -$0.79. This is an average of 8 analysts’ earnings, where the high earnings per share estimate is -$0.7 and the low earnings per share estimate is -$0.86.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The latest trade, Performances and Moving Averages give us the following Picture
The firm’s stock price fluctuated -0.37% within the last five trades and -6.20% within the last 30 trades, which was a significant change from the beginning of this year. Despite the fact that the share price decreased -50.78% in the last 6 months and -0.24% was subtracted to its value over the previous 3 months. REPL stock is trading at a margin of -4.37%, 0.91% and -41.43% apart from the 20-Day, 50-Day and 200-Day Simple Moving Average prices.
As of the close of trading, REPL deals in the Healthcare domain. The stock is trading -67.07 percent below its 52-week high and 38.71 percent above its 52-week low. For example, looking both at the price and the high and low measurements of 52 weeks will give you a clearer picture of the direction the price is heading. The firm’s Weighted Alpha is -42.3. A positive weighted alpha indicates the firm has done well over the course of the year, whereas one below 0 indicates that the firm has done poorly.
What Does Replimune Group Inc’s Profitability and Valuation Ratios Tell Us About the Stock?
With regard to the profitability of the company, the operating margin is currently at 0.00 percent. The profit margin, also known as the revenue ratio or gross profit ratio, is an efficiency figure used to estimate the business’s profitability by comparing net income and sales. The higher the number, the more profits are generated for the company and vice versa.
The stock’s market cap achieved a total value of $501.56 million as of the last trading session. Market capitalization is the total value of all outstanding shares of a corporation and it is used to measure a company’s market value. The firm managed a Price-to-Book ratio of 1.19, which equates the market value of a stock with its book value.
Is Insider Trading a Real Thing?
Almost all investors and traders prefer to invest in shares controlled by the management of a corporation as a management company will be more likely to run the business itself and to never conduct things against the management’s desires and will always try to do what is best for their shareholders. Currently, 27.08 percent of Replimune Group Inc shares are owned by insiders, and 88.88 percent are held by financial institutions. Xynos Konstantinos, the Chief Medical Officer at Replimune Group Inc (REPL) has sold 7,313 shares of firm on Nov 16 ’23 at a price of $10.92 against the total amount of $79858.0. In another inside trade, Sarchi Christopher, Chief Commercial Officer of Replimune Group Inc (NASDAQ:REPL) sold 5,255 shares of the firm on Nov 16 ’23 for a total worth of $57385.0 at a price of $10.92. An inside trade which took place on Sep 12 ’23, Chief Business Officer of Replimune Group Inc Esposito Pamela sold 300 shares of firm against total price of $6000.0 at the cost of $20.00 per share.
